AIDS research and human retroviruses

publication venue for

Isolation of cytomegalovirus-specific cytotoxic T-lymphocytes from gut-associated lymphoid tissue (GALT) of HIV type 1-infected subjects. 2000
HTLV-I infection of cerebrospinal fluid T cells from patients with chronic neurologic disease. 1987
Current HIV/SIV Reservoir Assays for Preclinical and Clinical Applications: Recommendations from the Experts 2022 NIAID Workshop Summary. 2023
Multiplex Analysis of Cytokines and Chemokines in Persons Aging With or Without HIV. 2023
Call for Papers: AIDS Research and Human Retroviruses.. 38. 2022
Immunologic Change over 72 Weeks Following Raltegravir- Versus Efavirenz-Based Therapy in HIV/HCV-Coinfected Individuals in Vietnam.. 38. 2022
Call for Papers: AIDS Research and Human Retroviruses.. 38. 2021
HIV-1 Exploits Transitions Between CD4⁺ T Cell Migration and Activation.. 38. 2021
Current Considerations for Clinical Management and Care of People with HIV: Findings from the 11th Annual International HIV and Aging Workshop.. 37. 2021
Effects of Brief Adjunctive Metformin Therapy in Virologically Suppressed HIV-Infected Adults on Polyfunctional HIV-Specific CD8 T Cell Responses to PD-L1 Blockade.. 37. 2020
Short Communication: Carotid Artery Plaque Burden in HIV Is Associated with Soluble Mediators and Monocytes.. 36. 2020
Short Communication: Metformin Reduces CD4 T Cell Exhaustion in HIV-Infected Adults on Suppressive Antiretroviral Therapy.. 36. 2020
White Blood Cell Counts, Lymphocyte Subsets, and Incident Diabetes Mellitus in Women Living With and Without HIV.. 36. 2019
A Novel HIV-1 Nef Mutation in a Primary Pediatric Isolate Impairs MHC-Class I Downregulation and Cytopathicity.. 36. 2019
Harvard HIV and Aging Workshop: Perspectives and Priorities from Claude D. Pepper Centers and Centers for AIDS Research.. 35. 2019
C1q/TNF-Related Proteins, HIV and HIV-Associated Factors, and Cardiometabolic Phenotypes in Middle-Aged Women.. 35. 2019
The Intimate Relationship Between CD4+ T Cell Morphology and HIV-1 Infection.. 35. 2019
Short Communication: Expression of Host Restriction Factors by Memory CD4+ T Cells Differs Between Healthy Donors and HIV-1-Infected Individuals with Effective Antiretroviral Therapy.. 35. 2018
Short Communication: Protective Efficacy of Broadly Neutralizing Antibody PGDM1400 Against HIV-1 Challenge in Humanized Mice.. 34. 2018
Influence of Biological Sex, Age, and HIV Status in an In Vitro Primary Cell Model of HIV Latency Using a CXCR4 Tropic Virus.. 34. 2018
Early Life HIV-1 Immunization: Providing a Window for Protection Before Sexual Debut.. 34. 2018
Genetic Variation of the Kinases That Phosphorylate Tenofovir and Emtricitabine in Peripheral Blood Mononuclear Cells.. 34. 2018
Ultra-Deep Sequencing Analysis on HIV Drug-Resistance-Associated Mutations Among HIV-Infected Individuals: First Report from the Philippines.. 33. 2017
Association of Tuberculosis Status with Neurologic Disease and Immune Response in HTLV-1 Infection.. 33. 2017
Plasminogen Activator Inhibitor-1 Predicts Negative Alterations in Whole-Body Insulin Sensitivity in Chronic HIV Infection.. 33. 2017
The Risk of Cardiovascular Disease, Diabetes, Liver-Related Outcomes, and Death Over 10 Years in HIV/HCV-Coinfected Patients With and Without Steatosis.. 32. 2016
The Neutralizing Antibody Response in an Individual with Triple HIV-1 Infection Remains Directed at the First Infecting Subtype.. 32. 2016
Short Communication: Virion Aggregation by Neutralizing and Nonneutralizing Antibodies to the HIV-1 Envelope Glycoprotein.. 31. 2015
Short Communication: Coronary Heart Disease Risk by Framingham Risk Score in Hepatitis C and HIV/Hepatitis C-Coinfected Persons.. 31. 2015
Characterization of lipid composition and high-density lipoprotein function in HIV-infected individuals on stable antiretroviral regimens.. 31. 2014
Albuminuria is associated with elevated acute phase reactants and proinflammatory markers in HIV-infected patients receiving suppressive combination antiretroviral therapy.. 30. 2014
Galectin-9 is rapidly released during acute HIV-1 infection and remains sustained at high levels despite viral suppression even in elite controllers.. 30. 2014
Prevalence of drug resistance in human immunodeficiency virus type 1-infected treatment-naive children in Pune, India.. 30. 2014
Plasma monocyte chemoattractant protein-1 and tumor necrosis factor-α levels predict the presence of coronary artery calcium in HIV-infected individuals independent of traditional cardiovascular risk factors.. 30. 2013
Human T cell lymphotropic virus type 1 infection among U.S. thalassemia patients.. 29. 2013
Short communication: HIV type 1 subtype C variants transmitted through the bottleneck of breastfeeding are sensitive to new generation broadly neutralizing antibodies directed against quaternary and CD4-binding site epitopes.. 29. 2013
Targeting of conserved gag-epitopes in early HIV infection is associated with lower plasma viral load and slower CD4(+) T cell depletion.. 29. 2013
Short communication: HIV type 1 accumulates in influenza-specific T cells in subjects receiving seasonal vaccination in the context of effective antiretroviral therapy.. 28. 2012
Occluding the mannose moieties on human immunodeficiency virus type 1 gp120 with griffithsin improves the antibody responses to both proteins in mice.. 28. 2011
Surveillance of transmitted HIV type 1 drug resistance among HIV type 1-positive women attending an antenatal clinic in Kakinada, India.. 27. 2011
Genetic Conservation in gp36 Transmembrane Sequences of Indian HIV Type 2 Isolates.. 27. 2011
A comparison of treatment eligibility for hepatitis C virus in HCV-monoinfected versus HCV/HIV-coinfected persons in electronically retrieved cohort of HCV-infected veterans.. 27. 2011
Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals.. 27. 2010
Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults.. 27. 2010
Characterization of SIV in the oral cavity and in vitro inhibition of SIV by rhesus macaque saliva.. 26. 2010
Transmitted HIV drug resistance among HIV-infected voluntary counseling and testing centers (VCTC) clients in Mumbai, India.. 26. 2010
IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines.. 26. 2010
One-, two-, and three-class resistance among HIV-infected patients on antiretroviral therapy in private care clinics: Mumbai, India.. 26. 2010
Short communication: Methamphetamine treatment increases in vitro and in vivo HIV replication.. 25. 2009
HIV-1-specific T Cell-dependent natural killer (NK) cell activation: major contribution by NK cells to interferon-gamma production in response to HIV-1 antigens.. 25. 2009
High frequency of vitamin D deficiency in ambulatory HIV-Positive patients.. 25. 2009
CD4+ T-cell decline after the interruption of antiretroviral therapy in ACTG A5170 is predicted by differential expression of genes in the ras signaling pathway.. 24. 2008
Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection.. 24. 2008
Brain magnetic resonance imaging white matter lesions are frequent in HTLV-I carriers and do not discriminate from HAM/TSP.. 23. 2007
Purified, proteolytically mature HIV type 1 SOSIP gp140 envelope trimers.. 23. 2007
Clinical manifestations associated with HTLV type I infection: a cross-sectional study.. 23. 2007
Construction and characterization of soluble, cleaved, and stabilized trimeric Env proteins based on HIV type 1 Env subtype A.. 22. 2006
Factors associated with poor immunologic response to virologic suppression by highly active antiretroviral therapy in HIV-infected women.. 22. 2006
Detection of T lymphocytes specific for human endogenous retrovirus K (HERV-K) in patients with seminoma.. 22. 2006
A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087.. 21. 2005
Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: a randomized, placebo-controlled trial, ACTG 307.. 20. 2004
Evolutionary repair of HIV type 1 gp41 with a kink in the N-terminal helix leads to restoration of the six-helix bundle structure.. 20. 2004
Protease and reverse transcriptase mutation patterns in HIV type 1 isolates from heavily treated persons: comparison of isolates from Northern California with isolates from other regions.. 19. 2003
Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types.. 19. 2003
Boosting of SIV-specific T cell responses in rhesus macaques that resist repeated intravaginal challenge with SIVmac251.. 18. 2002
Human immunodeficiency virus type 1 Nef mediates activation of STAT3 in immature dendritic cells.. 18. 2002
Dendritic cell amplification of HIV type 1-specific CD8+ T cell responses in exposed, seronegative heterosexual women.. 18. 2002
Impact of antiretroviral therapy on decreasing hospitalization rates of HIV-infected patients in 2001.. 18. 2002
HIV type 1 molecular clones able to use the Bonzo/STRL-33 coreceptor for virus entry.. 17. 2001
Evaluation of a lipopeptide immunogen as a therapeutic in HIV type 1-seropositive individuals.. 16. 2000
Parameters influencing measurement of the Gag antigen-specific T-proliferative response to HIV type 1 infection.. 16. 2000
Identification of subdominant cytotoxic T lymphocyte epitopes encoded by autologous HIV type 1 sequences, using dendritic cell stimulation and computer-driven algorithm.. 16. 2000
Expression patterns of the HIV type 1 coreceptors CCR5 and CXCR4 on CD4+ T cells and monocytes from cord and adult blood.. 14. 1998
Interactions of polyclonal and monoclonal anti-glycoprotein 120 antibodies with oligomeric glycoprotein 120-glycoprotein 41 complexes of a primary HIV type 1 isolate: relationship to neutralization.. 14. 1998
Analysis of the interaction of antibodies with a conserved enzymatically deglycosylated core of the HIV type 1 envelope glycoprotein 120.. 14. 1998
Interaction of pregnancy steroid hormones and zidovudine in inhibition of HIV type 1 replication in monocytoid and placental Hofbauer cells: implications for the prevention of maternal-fetal transmission of HIV.. 13. 1997
An investigation of the high-avidity antibody response to glycoprotein 120 of human immunodeficiency virus type 1.. 13. 1997
Cytotoxic monocytes in the blood of HIV type 1-infected subjects destroy targeted T cells in a CD95-dependent fashion.. 13. 1997
Determining neutralization serotypes of HIV type 1 by neural networks.. 12. 1996
Differential production of interleukin 10 during human immunodeficiency virus infection.. 12. 1996
Altered CD4 interactions of HIV type 1 LAI variants selected for the capacity to induce membrane fusion in the presence of a monoclonal antibody to domain 2 of CD4.. 12. 1996
AIDS patient monocytes target CD4 T cells for cellular conjugate formation and deletion through the membrane expression of HIV-1 envelope molecules.. 12. 1996
Effect of interleukin 12 on in vitro HIV type 1 replication depends on clinical stage.. 12. 1996
Mutations in the vpu, env, and nef genes of a syncytium-inducing variant of HIV type 1 JR-CSF that infects a range of T cell lines.. 12. 1996
Soluble CD4 induces the binding of human immunodeficiency virus type 1 to cells via the V3 loop of glycoprotein 120 and specific sites in glycoprotein 41.. 12. 1996
Bathophenanthroline disulfonate and soluble CD4 as probes for early events of HIV type 1 entry.. 11. 1995
Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies.. 10. 1994
Feasibility and cohort development for HIV vaccine trials in Haiti.. 10 Suppl 2. 1994
Antigenic variation in gp120s from molecular clones of HIV-1 LAI.. 9. 1993
Detecting SIV gp120 and its interaction with soluble CD4 by ELISA.. 9. 1993
Nonaffinity purification of recombinant gp120 for use in AIDS vaccine development.. 9. 1993
A hidden region in the third variable domain of HIV-1 IIIB gp120 identified by a monoclonal antibody.. 9. 1993
Soluble CD4 and CD4 immunoglobulin-selected HIV-1 variants: a phenotypic characterization.. 9. 1993
Adaptation of two primary human immunodeficiency virus type 1 isolates to growth in transformed T cell lines correlates with alterations in the responses of their envelope glycoproteins to soluble CD4.. 9. 1993
The reactivities of HIV-1+ human sera with solid-phase V3 loop peptides can be poor predictors of their reactivities with V3 loops on native gp120 molecules.. 9. 1993
Effect of mutations in the V3 loop of HIV-1 gp120 on infectivity and susceptibility to proteolytic cleavage.. 9. 1993
Identification of human immunodeficiency virus type 1 glycoprotein gp120/gp41 interacting sites by the idiotypic mimicry of two monoclonal antibodies.. 9. 1993
Conserved structural features in the interaction between retroviral surface and transmembrane glycoproteins?. 8. 1992
Human immunodeficiency virus variants that escape cytotoxic T-cell recognition.. 8. 1992
Lymphocytes from some long-term seronegative heterosexual partners of HIV-infected individuals proliferate in response to HIV antigens.. 8. 1992
The urge for an AIDS vaccine: perspectives from a developing country.. 8. 1992
Monoclonal antibodies to the C4 region of human immunodeficiency virus type 1 gp120: use in topological analysis of a CD4 binding site.. 8. 1992
Thermodynamic and kinetic analysis of sCD4 binding to HIV-1 virions and of gp120 dissociation.. 8. 1992
Investigations into the mechanism by which sulfated polysaccharides inhibit HIV infection in vitro.. 8. 1992
The V3 loops of the HIV-1 and HIV-2 surface glycoproteins contain proteolytic cleavage sites: a possible function in viral fusion?. 7. 1991
Enhancement of soluble CD4-mediated HIV neutralization and gp 120 binding by CD4 autoantibodies and monoclonal antibodies.. 6. 1990
Expression of HIV-1 gp120 and human soluble CD4 by recombinant baculoviruses and their interaction in vitro.. 6. 1990
Prognostic significance of quantitative levels of HIV p24 binding capacity in HIV infection.. 6. 1990
Levels of soluble CD8 antigen and circulating immune complexes in intravenous drug abusers: relationships to HIV antibody serology.. 5. 1989
Sensitive ELISA for the gp120 and gp160 surface glycoproteins of HIV-1.. 4. 1988
Prior Case of Resistance on Dolutegravir Plus Lamivudine Dual Therapy. 2020
Human T-lymphotropic virus 1, breastfeeding, and antiretroviral therapy. 2014
Inhibition of tat-activated, HIV-1 long terminal repeat-mediated gene expression by glucocorticoids. 1993
Advances in AIDS Vaccine Development: 5th Annual meeting of the National Cooperative Vaccine Development Groups for AIDS. Chantilly, Virginia, August 30-September 3, 1992. Proceedings and abstracts. 1993
Update: HIV-1 gene nomenclature.. 4. 1988
Macrophage biology, latency, and HIV infection.. 4. 1988
Histoarchitectural Deterioration of Lymphoid Tissues in HIV-1 Infection and in Aging. 2019
How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development? 2011
V3: HIV's switch-hitter. 2005
The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. 2004
HIV type 1 coreceptors, neutralization serotypes, and vaccine development. 1997
The beta-chemokines, HIV type 1 second receptors, and exposed uninfected persons. 1996
AIDS research: the second decade. 1994
Molecular pathogenesis of HIV-associated lymphomas. 1992
Immunology of HIV infection, I: Biology of the interferons. 1990
Novel vaccination and antireceptor strategies against HIV. 1990

VIVO Weill Cornell Medical College

AIDS research and human retroviruses Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)